Federal grants to Helixbind, Inc.
Helixbind, Inc. in Marlborough, Massachusetts received $27.1 million in federal grants from fiscal 2021 to 2025, across 12 awards. Its largest program was Allergy and Infectious Diseases Research, with $27.1 million. In fiscal 2025 it was awarded $5.1 million.
From USAspending.gov award records, updated November 7, 2026.
- Grants, FY 2021 to 2025$27.1 million
- Awards12
- Awarded in FY 2025$5.1 million
- Largest award$3.0 million
By year
| Fiscal year | Awards | Amount |
|---|---|---|
| FY 2021 | 0 | $0 |
| FY 2022 | 7 | $7.0 million |
| FY 2023 | 7 | $7.0 million |
| FY 2024 | 8 | $8.0 million |
| FY 2025 | 5 | $5.1 million |
Programs that fund Helixbind, Inc.
| Program | Awards | Amount |
|---|---|---|
| Allergy and Infectious Diseases Research | 12 | $27.1 million |
Awarding agencies
| Agency | Awards | Amount |
|---|---|---|
| Department of Health and Human Services | 12 | $27.1 million |
Largest awards
| Award | Program | First action | Amount |
|---|---|---|---|
| Direct detection and identification of antimicrobial resistance genes in bloodstream infections - project summary leading to over 270,000 deaths in the us annually, septicemia is the systemic inflammatory response to a bloodstream infection (BSI). Timely diagnosis and treatment of bsis has been demo | Allergy and Infectious Diseases Research | August 9, 2022 | $3.0 million |
| Diagnostic tool for assessment and tracking of microbial load in bloodstream infections - project summary leading to over 270,000 deaths in the us annually, septicemia is the systemic inflammatory response to a bloodstream infection (BSI). Early diagnosis and treatment of bsis have demonstrated impr | Allergy and Infectious Diseases Research | June 23, 2023 | $3.0 million |
| Commercialization readiness pilot (CRP) program support for: an integrated device for identification of bloodstream infections directly from blood - project summary leading to over 270,000 deaths in the us annually, septicemia is the systemic inflammatory response to a bloodstream infection (BSI). E | Allergy and Infectious Diseases Research | March 3, 2022 | $3.0 million |
| Commercialization readiness pilot (CRP) program support for: direct-from-specimen identification of pathogens common in endocarditis - project summary infective endocarditis (IE) occurs when bacteria or fungi adhere to the endocardial surface forming small lesions. This invasive disease is character | Allergy and Infectious Diseases Research | June 20, 2023 | $3.0 million |
| Direct from blood identification of bloodstream infections in newborns - project summary neonatal sepsis is a life-threatening disease that affects 2 out of every 1,000 live births in the us. Caused by an invasive bloodstream infection (BSI) occurring either at the time of birth or soon thereafter, | Allergy and Infectious Diseases Research | August 1, 2022 | $3.0 million |
| An automated platform for direct-from-specimen identification of pathogens common in endocarditis | Allergy and Infectious Diseases Research | January 9, 2024 | $2.1 million |
| An automated culture-free system for the identification of bloodstream infections direct from blood - project summary leading to over 270,000 deaths in the us annually, septicemia is the systemic inflammatory response to a bloodstream infection (BSI). Studies have shown that early detection and the | Allergy and Infectious Diseases Research | July 8, 2024 | $2.0 million |
| Commercialization readiness pilot (CRP) program support for: ultra-sensitive, direct-from-blood, molecular detection of borrelia infections. - project summary lyme disease (LD), caused by the tick-borne bacteria borrelia, is the most common vector-borne infectious disease in the us with 300,000 new | Allergy and Infectious Diseases Research | April 2, 2024 | $2.0 million |
| Massively multiplexed dsdna invasion arrays - project summary septicemia, induced by an invasive microbial bloodstream infection (BSI), is a significant healthcare burden, accounting for over 1.7M cases annually just in the us. Characterized by high mortality rates (~20%), prognosis for septic patie | Allergy and Infectious Diseases Research | April 1, 2022 | $2.0 million |
| An integrated device for rapid bacteremia diagnosis from whole blood | Allergy and Infectious Diseases Research | February 13, 2021 | $2.0 million |
Questions people ask
How much federal grant money does Helixbind, Inc. get?
$27.1 million in 12 grant awards from fiscal 2021 to 2025, as obligations reported to USAspending.gov.
Which agency gives Helixbind, Inc. the most?
The Department of Health and Human Services, with $27.1 million in 12 awards.
What is Helixbind, Inc.'s largest federal grant?
$3.0 million under Allergy and Infectious Diseases Research, with its first action in the period on August 9, 2022. That counts only the money obligated in fiscal 2021 to 2025.
Other grant recipients in Marlborough
Largest federal grant recipients in Massachusetts · Federal grants in Massachusetts